Evidence map›Paper›PMID 23881495›Full record

ArticleNature chemistry2013

Single-molecule interrogation of a bacterial sugar transporter allows the discovery of an extracellular inhibitor.

Lingbing Kong, Leon Harrington, Qiuhong Li, Stephen Cheley, Benjamin G Davis, Hagan Bayley

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Design and Assembly of Transmembrane Helix Barrel.The Journal of membrane biology · 2020
    Article
  5. Review
  6. Targeting the Sugary Armor ofFrontiers in cellular and infection microbiology · 2019
    Review
  7. Article
  8. Article
  9. Frontiers in microbiology · 2017
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Multivalent Inhibitors of Channel-Forming Bacterial Toxins.Current topics in microbiology and immunology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lingbing KongDepartment of Chemistry, University of Oxford, Chemical Research Laboratory, Mansfield Road, Oxford OX1 3TA, UK.
Leon Harrington
Qiuhong Li
Stephen Cheley
Benjamin G Davis
Hagan Bayley
University of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E004350/1Biotechnology and Biological Sciences Research Council EGA17763Medical Research Council G0300122Wellcome Trust
6 · The paper itself

Abstract

Capsular polysaccharides form the outermost protective layer around many Gram-negative bacteria. Antibiotics aimed directly at weakening this layer are not yet available. In pathogenic Escherichia coli E69, a protein, Wza, forms a pore in the outer membrane that transports K30 capsular polysaccharide from its site of synthesis to the outside of the cell. This therefore represents a prospective antibiotic target. Here we test a variety of grommet-like mimics of K30 capsular polysaccharide on wild-type Wza and on mutant open forms of the pore by electrical recording in planar lipid bilayers. The most effective glycomimetic was the unnatural cyclic octasaccharide octakis(6-deoxy-6-amino)cyclomaltooctaose (am8γCD), which blocks the α-helix barrel of Wza, a site that is directly accessible from the external medium. This glycomimetic inhibited K30 polysaccharide transport in live E. coli E69. With the protective outer membrane disrupted, the bacteria can be recognized and killed by the human immune system.

Indexed as

Carbohydrate MetabolismCarrier ProteinsEscherichia coliCarrier Proteins

Identifiers

PMID23881495
OpenAlexW2171780257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.